



# Newsletter CTCTrap



At the annual meeting of the American Association for Cancer Research in April 2015 in Philadelphia (USA) results of the CTCTrap program were presented and the participation of CTCTrap in CANCER-ID announced. [CANCER-ID](#) (is a public-private partnership supported by Europe's Innovative Medicines Initiative (IMI) with currently 38 partners and is aiming at the establishment of standard protocols for and clinical validation of blood-based biomarkers. Technology to identify and characterize tumor cells in blood developed in the CTCTrap consortium will be validated in CANCER-ID in Non-Small Cell Lung Cancer and Her2 resistant breast cancer. The technologies and protocols as developed within CTCTrap by SMEs Leukocare, Aquamarijn and the academic partners from IOV, Gustave Roussy, Heinrich Heine and the University of Twente will be used within CANCER-ID. With the emergence of different technologies for CTC enumeration a large variation of reported results are obtained urging the need for standardization of the definitions used to classify objects / cells as CTC. To address this issue CTCTrap started the development of an open source image analysis algorithm to aid in the classification of objects as CTC. This will be continued and improved upon in CANCER-ID. Experience gained by the CTCTrap consortium is that standardization of microscope equipment and staining procedures are essential but not trivial. Reagents, staining procedures and minimum microscope requirements have now been set and patient studies can start in which results obtained between different sites are truly comparable. The figure illustrated typical images obtained after filtration of the blood discarded by the CellSearch system.

The same procedure will be used for the Diagnostic LeukApheresis (DLA). Ethical approvals to perform DLA at the CTCTrap clinical sites have been obtained and comparison aliquots of these DLA will be interrogated for the presence of CTC.



*Staining of cells captured on microsieves, yellow (cytokeratin, tumor cells), red (CD45, leukocytes), blue (DAPI, nucleus) presented at the annual meeting of the American Association for Cancer Research April 2015 in Philadelphia.*

## CTCTrap consortium



For more information on CTCTrap please visit our website: [www.tnw.utwente.nl/ctctrap](http://www.tnw.utwente.nl/ctctrap) or contact [mcbp@tnw.utwente.nl](mailto:mcbp@tnw.utwente.nl)

**UNIVERSITY OF TWENTE.**